Cyclophosphamide as a first-line therapy in LGL leukemia

A. Moignet (1) , Z. Hasanali (2) , R. Zambello (3) , L. Pavan (3) , B. Bareau (4) , O. Tournilhac (5) , Mikaël Roussel (1) , T. Fest (1, 6) , A. Awwad (2) , K. Baab (2) , G. Semenzato (3) , R. Houot (1, 6) , T. P. Loughran (2) , T. Lamy (1, 6)

1 CHU Pontchaillou [Rennes]
2 Milton S. Hershey Medical Center
3 Unipd - Università degli Studi di Padova = University of Padua
4 Department of Clinical Hematology
5 CHU Clermont-Ferrand
6 CIC - Centre d'Investigation Clinique [Rennes]

Keywords: Adult; Aged; 80 and over; Antineoplastic Agents; Alkylating; Cyclophosphamide; Female; Humans; Leukemia; Large Granular Lymphocytic; Male; Middle Aged

Domains: Life Sciences [q-bio]

A. Moignet, Z. Hasanali, R. Zambello, L. Pavan, B. Bareau, et al.. Cyclophosphamide as a first-line therapy in LGL leukemia. Leukemia, 2014, 28 (5), pp.1134--1136. ⟨10.1038/leu.2013.359⟩. ⟨hal-01147023⟩